MA37438A1 - Procédés de traitement du cancer utilisant des inhibiteurs de la kinase aurora - Google Patents

Procédés de traitement du cancer utilisant des inhibiteurs de la kinase aurora

Info

Publication number
MA37438A1
MA37438A1 MA37438A MA37438A MA37438A1 MA 37438 A1 MA37438 A1 MA 37438A1 MA 37438 A MA37438 A MA 37438A MA 37438 A MA37438 A MA 37438A MA 37438 A1 MA37438 A1 MA 37438A1
Authority
MA
Morocco
Prior art keywords
kinase inhibitors
cancer treatment
treatment methods
aurora kinase
treatment
Prior art date
Application number
MA37438A
Other languages
English (en)
Inventor
Arijit Chakravarty
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MA37438A1 publication Critical patent/MA37438A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des procédés pour le traitement de divers troubles prolifératifs cellulaires. L'invention concerne en particulier des procédés pour le traitement de divers troubles prolifératifs cellulaires par administration d'un inhibiteur sélectif de la kinase aurora a en combinaison avec une chimiothérapie à base de taxane, tel que le paclitaxel ou le docétaxel.
MA37438A 2012-03-20 2013-03-19 Procédés de traitement du cancer utilisant des inhibiteurs de la kinase aurora MA37438A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261613258P 2012-03-20 2012-03-20
PCT/US2013/032962 WO2013142491A1 (fr) 2012-03-20 2013-03-19 Procédés de traitement du cancer utilisant des inhibiteurs de la kinase aurora

Publications (1)

Publication Number Publication Date
MA37438A1 true MA37438A1 (fr) 2016-05-31

Family

ID=48048255

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37438A MA37438A1 (fr) 2012-03-20 2013-03-19 Procédés de traitement du cancer utilisant des inhibiteurs de la kinase aurora

Country Status (24)

Country Link
US (2) US20130303519A1 (fr)
EP (1) EP2827855B1 (fr)
JP (1) JP6373252B2 (fr)
KR (1) KR102128866B1 (fr)
CN (1) CN104271129A (fr)
AU (1) AU2013235275B2 (fr)
CA (1) CA2868024A1 (fr)
EA (1) EA036434B1 (fr)
ES (1) ES2746946T3 (fr)
GE (2) GEAP201813599A (fr)
IL (1) IL234686B (fr)
IN (1) IN2014DN08477A (fr)
JO (1) JO3630B1 (fr)
MA (1) MA37438A1 (fr)
MX (1) MX358411B (fr)
MY (1) MY175225A (fr)
NZ (1) NZ700744A (fr)
PH (1) PH12014502109A1 (fr)
SG (2) SG10201607741RA (fr)
TN (1) TN2014000387A1 (fr)
TW (1) TWI649082B (fr)
UA (1) UA117455C2 (fr)
WO (1) WO2013142491A1 (fr)
ZA (1) ZA201407551B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
WO2016106357A1 (fr) * 2014-12-23 2016-06-30 Millennnium Pharmaceuticals, Inc. Combinaison d'inhibiteurs de raf et d'inhibiteurs de kinases aurora
EP3317427B1 (fr) * 2015-07-02 2020-12-23 Millennium Pharmaceuticals, Inc. Biomarqueurs de réponse à des inhibiteurs sélectifs d'aurora a kinase
CN114681455A (zh) * 2018-08-17 2022-07-01 深圳微芯生物科技股份有限公司 组蛋白去乙酰化酶抑制剂与蛋白激酶抑制剂之组合及其制药用途

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
FR2450833A1 (fr) 1979-02-07 1980-10-03 Hoffmann La Roche Derives de benzazepine
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (fr) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-Benzazépines à cycles hétérocycliques de 5 et 6 côtés
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5747487A (en) 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
NZ330973A (en) 1996-03-08 2000-03-27 Zeneca Ltd Azolobenzazepine derivatives as neurologically active agents
AU5330698A (en) 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
IL135303A0 (en) 1997-09-29 2001-05-20 Meiji Seika Kaisha Tricyclic triazolobenzazepine derivatives, process for producing the same and antiallergic agents
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
AU4841700A (en) 1999-05-12 2000-11-21 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
ES2266258T3 (es) 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina cinasas.
EP1345925B1 (fr) 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Composes de pyrazole presentant une grande utilite comme inhibiteurs de proteine kinase
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
WO2003013545A1 (fr) 2001-08-09 2003-02-20 Actelion Pharmaceuticals Ltd Heterocycles a fusion benzo utilises comme antagonistes vis-a-vis de l'endotheline
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
JP2007522217A (ja) 2004-02-10 2007-08-09 サンタラス インコーポレイティッド プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ
ATE381566T1 (de) 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
US8153630B2 (en) 2004-11-17 2012-04-10 Miikana Therapeutics, Inc. Kinase inhibitors
WO2006070198A1 (fr) 2004-12-30 2006-07-06 Astex Therapeutics Limited Derives pyrazoliques modulant l'activite des kinases cdk, gsk et aurora
ES2408318T3 (es) 2005-12-23 2013-06-20 Glaxosmithkline Llc Inhibidores de azaindol de las cinasas Aurora
EP1973532A1 (fr) 2006-01-16 2008-10-01 Jubilant Organosys Limited Formulation pharmaceutique stable d'un compose labile a base d'acide et son procede de preparation
WO2008020314A2 (fr) 2006-03-14 2008-02-21 Ranbaxy Laboratories Limited Formulations de dosage stabilisantes à base de statine
DE102006012301A1 (de) 2006-03-15 2007-09-20 Cemag-Anlagenbau-Dessau Gmbh Herstellung von Zementklinker
WO2008021038A2 (fr) 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazépines et méthodes d'inhibition de la progression mitotique
WO2008054808A2 (fr) 2006-10-31 2008-05-08 Achillion Pharmaceuticals, Inc. Compositions pharmaceutiques d'elvucitabine
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
AR065802A1 (es) 2007-03-22 2009-07-01 Schering Corp Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US20090203671A1 (en) 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
WO2009114703A2 (fr) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Thérapie combinée pour le traitement d'un cancer
KR102080429B1 (ko) 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
JP2013520424A (ja) 2010-02-19 2013-06-06 ミレニアム ファーマシューティカルズ， インコーポレイテッド ナトリウム４−｛［９−クロロ−７−（２−フルオロ−６−メトキシフェニル）−５Ｈ−ピリミド［５，４−ｄ］［２］ベンゾアゼピン−２−イル］アミノ｝−２−メトキシベンゾエートの結晶形
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors

Also Published As

Publication number Publication date
MY175225A (en) 2020-06-16
IL234686B (en) 2020-01-30
GEAP201813599A (en) 2018-06-25
US10213436B2 (en) 2019-02-26
UA117455C2 (uk) 2018-08-10
IL234686A0 (en) 2014-11-30
JO3630B1 (ar) 2020-08-27
NZ700744A (en) 2016-09-30
TN2014000387A1 (en) 2015-12-21
IN2014DN08477A (fr) 2015-05-08
SG11201405621UA (en) 2014-10-30
EP2827855B1 (fr) 2019-06-26
EA201491727A1 (ru) 2015-01-30
SG10201607741RA (en) 2016-11-29
US20160193224A1 (en) 2016-07-07
AU2013235275B2 (en) 2017-12-07
TW201343169A (zh) 2013-11-01
KR102128866B1 (ko) 2020-07-01
MX2014011324A (es) 2014-12-05
HK1206253A1 (en) 2016-01-08
KR20140144215A (ko) 2014-12-18
AU2013235275A1 (en) 2014-10-23
MX358411B (es) 2018-08-20
ES2746946T3 (es) 2020-03-09
JP2015510945A (ja) 2015-04-13
TWI649082B (zh) 2019-02-01
GEP20186900B (en) 2018-10-10
ZA201407551B (en) 2019-01-30
PH12014502109A1 (en) 2014-12-10
EP2827855A1 (fr) 2015-01-28
EA036434B1 (ru) 2020-11-10
CN104271129A (zh) 2015-01-07
CA2868024A1 (fr) 2013-09-26
WO2013142491A1 (fr) 2013-09-26
JP6373252B2 (ja) 2018-08-15
US20130303519A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
MX2018004832A (es) Selectividad de mutante y combinaciones de un compuesto inhibidor de fosfoinositida 3 cinasa y agentes quimioterapeuticos para el tratamiento de cancer.
MA38959A1 (fr) Modulateurs du facteur b du complément
MA39906A (fr) Polythérapies pour le traitement du cancer
MX2016016744A (es) Inhibidores de ezh2 para tratar linfomas.
MY188911A (en) Methods of treating bladder cancer
MX351148B (es) Formulacion de anticuerpo beta amiloide.
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
CL2013003160A1 (es) Compuestos derivados de 4h-cromen-4-ona moduladores de la proteina cinasa pi3k; compuestos intermediarios; composicion farmaceutica que los comprende; y utiles en el tratamiento del cancer, agentes antinflamatorios, inmunosupresores, esteroides, analgesicos, leucemia, entre otros.
TR201816379T4 (tr) DNA-PK inhibitörleri.
PA8851101A1 (es) Compuesto amino pirazol
MX2012001877A (es) Ligandos sigma para la prevencion o el tratamiento de dolor inducido por quimioterapia.
GB201204263D0 (en) Giloma treatment
EA201491647A1 (ru) Основанные на арилэфирах ингибиторы киназ
MA39170B1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MX2012013495A (es) Ligandos sigma para la revolucion y/o el tratamiento de la emesis inducida por quimioterapia o radioterapia.
MA34952B1 (fr) Combinaisons comprenant du macitentan pour le traitement d'un glioblastome multiforme
JOP20170115B1 (ar) مشتقات بيريدينيل، تركيبات صيدلية منها واستخداماتها كمثبطات aoc3
IN2014DN08477A (fr)
EA201500368A1 (ru) Фармацевтическая композиция 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей для лечения кардиоваскулярной патологии
EA201692531A1 (ru) Способы лечения инфекций
NZ711046A (en) Nanoparticles containing a taxane and their use
MA43609B1 (fr) Compositions et méthodes de traitement de l'anémie
CL2015000874A1 (es) Pde9i con estructura principal de imidazopirazinona